Yahoo Finance

Operations: Surgical Science Sweden AB generates revenue from two main segments: Industry/OEM at SEK441.59 million and Educational Products at SEK442.50 million.

Estimated Discount To Fair Value: 44.8%

Surgical Science Sweden AB is trading at SEK 150.7, significantly below its estimated fair value of SEK 273.16, highlighting potential undervaluation based on cash flows. Despite a decline in profit margins from last year's 26.5% to 14.9%, the company reported strong Q1 earnings growth, with net income rising to SEK 33.24 million from SEK 23.79 million year-on-year and forecasts indicating robust annual earnings growth of over 20%, surpassing Swedish market averages.

• The growth report we've compiled suggests that Surgical Science Sweden's future prospects could be on the up.

• Click to explore a detailed breakdown of our findings in Surgical Science Sweden's balance sheet health report.

Schaeffler

Overview: Schaeffler AG, along with its subsidiaries, develops, manufactures, and sells components and systems for industrial applications across Europe, the Americas, China, and the Asia Pacific with a market cap of approximately €3.87 billion.

Operations: The company's revenue segments include Vehicle Lifetime Solutions with €2.73 billion and Bearings & Industrial Solutions with €6.53 billion.

Estimated Discount To Fair Value: 27.5%

Schaeffler is trading at €4.10, significantly below its estimated fair value of €5.65, suggesting undervaluation based on cash flows. Despite recent challenges, including a decline in net income from €231 million to €83 million year-on-year for Q1 2025, the company anticipates becoming profitable within three years. Schaeffler's strategic shift towards cloud-based solutions and its merger with Vitesco Technologies may enhance operational efficiencies and support future growth prospects amidst industry competition.

• Insights from our recent growth report point to a promising forecast for Schaeffler's business outlook.

• Click here to discover the nuances of Schaeffler with our detailed financial health report.

Where To Now?

• Get an in-depth perspective on all 173 Undervalued European Stocks Based On Cash Flows by using our screener here.

• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.

• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ENXTAM:BESI OM:SUS and XTRA:SHA0.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com